Search hospitals > Quebec > SHERBROOKE
CHUS - Hopital Fleurimont
Claim this profileSHERBROOKE, Quebec J1H 5N4
Global Leader in Cancer
Global Leader in Prostate Cancer
Conducts research for Breast Cancer
Conducts research for Brain Tumor
Conducts research for Lung Cancer
170 reported clinical trials
13 medical researchers
Summary
CHUS - Hopital Fleurimont is a medical facility located in SHERBROOKE, Quebec. This center is recognized for care of Cancer, Prostate Cancer, Breast Cancer, Brain Tumor, Lung Cancer and other specialties. CHUS - Hopital Fleurimont is involved with conducting 170 clinical trials across 245 conditions. There are 13 research doctors associated with this hospital, such as Josee Brossard, Paul Bessette, MD, Frederic Lemay, and Valerie Theberge.Area of expertise
1Cancer
Global LeaderStage III
Stage IV
Stage I
2Prostate Cancer
Global LeaderStage I
Stage II
Top PIs
Josee BrossardCentre Hospitalier Universitaire de Sherbrooke-Fleurimont4 years of reported clinical research
Studies Brain Tumor
Studies Tumors
18 reported clinical trials
58 drugs studied
Paul Bessette, MDCHUS - Hôpital Fleurimont4 years of reported clinical research
Studies Ovarian Cancer
Studies Fallopian Tube Cancer
8 reported clinical trials
12 drugs studied
Frederic LemayCentre Hospitalier Universitaire de Sherbrooke-Fleurimont4 years of reported clinical research
Studies Colorectal Cancer
Studies Pancreatic Adenocarcinoma
6 reported clinical trials
18 drugs studied
Valerie ThebergeCHU de Quebec-L'Hotel-Dieu de Quebec (HDQ)1 year of reported clinical research
Studies Breast Cancer
Studies Radiotherapy
6 reported clinical trials
14 drugs studied
Clinical Trials running at CHUS - Hopital Fleurimont
Prostate Cancer
Astrocytoma
Low Grade Glioma
Brain Tumor
Ovarian Tumors
Cancer
Testicular Carcinoma
Ovarian Carcinoma
Ovarian Choriocarcinoma
Tumors
Radiotherapy
for High Risk Prostate Cancer
In North America, the number of new cases of prostate cancer increases every year. Many efforts have been made to develop more efficient and safer curative treatments for high risk prostate cancer patients. This phase III clinical trial is designed to compare the safety of a standard pelvic external beam radiation therapy (EBRT) combined with a high dose rate brachytherapy (HDRB) boost (direct insertion of radiation source over a period of minutes via flexible needles temporarily inserted in the prostate) to a shorter course of hypofractionated dose escalation radiotherapy (larger radiation dose per daily treatment) in patients with high risk prostate cancer. The investigators plan to recruit 296 patients across Quebec who will be randomized in either treatment plan.
Recruiting2 awards Phase 39 criteria
Hormone + Radiation Therapy
for Prostate Cancer
This phase III trial compares less intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in treating patients with high risk prostate cancer and low gene risk score. This trial also compares more intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in patients with high risk prostate cancer and high gene risk score. Apalutamide may help fight prostate cancer by blocking the use of androgen by the tumor cells. Radiation therapy uses high energy rays to kill tumor cells and shrink tumors. Giving a shorter hormone therapy treatment may work the same at controlling prostate cancer compared to the usual 24 month hormone therapy treatment in patients with low gene risk score. Adding apalutamide to the usual treatment may increase the length of time without prostate cancer spreading as compared to the usual treatment in patients with high gene risk score.
Recruiting2 awards Phase 36 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at CHUS - Hopital Fleurimont?
CHUS - Hopital Fleurimont is a medical facility located in SHERBROOKE, Quebec. This center is recognized for care of Cancer, Prostate Cancer, Breast Cancer, Brain Tumor, Lung Cancer and other specialties. CHUS - Hopital Fleurimont is involved with conducting 170 clinical trials across 245 conditions. There are 13 research doctors associated with this hospital, such as Josee Brossard, Paul Bessette, MD, Frederic Lemay, and Valerie Theberge.